Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data

Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data

Background/AimsThe introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are th...

Full description

Bibliographic Details
Main Authors: Moran Ki, Hwa Young Choi, Kyung-Ah Kim, Eun Sun Jang, Sook-Hyang Jeong
Format: Article
Language:English
Published: Gastroenterology Council for Gut and Liver 2017-11-01
Series:Gut and Liver
Subjects:
antiviral agents
costs and cost analysis
hepatitis c
chronic
pegylated interferon
ribavirin
Online Access:http://gutnliver.org/journal/view.html?doi=10.5009/gnl17034

Internet

http://gutnliver.org/journal/view.html?doi=10.5009/gnl17034

Similar Items